<DOC>
	<DOC>NCT00562809</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of Irbesartan 150/12.5 mg and 300/25 mg in patients with hypertension not controlled by monotherapy.</brief_summary>
	<brief_title>The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension</brief_title>
	<detailed_description>The primary and secondary endpoints applied to sub-groups defined by age, race, diabetes, metabolic syndrome and prior HTN therapy.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>The patient must have hypertension and uncontrolled SBP on monotherapy. Patients who have read, signed and received a copy of the informed consent prior to any study procedures Note: Female patients must be postmenopausal for one year, surgically sterilized, or using a medically accepted method of contraception (intrauterine device, oral contraceptives, barrier method with spermicide) and must agree to use an effective method of contraception throughout the study. Any history of secondary hypertension History of hypertensive encephalopathy, stroke, or transient ischemic attack (TIA) within the past 12 months History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>